Coelho Rogerio Vivaldi's Net Worth

$3.76 Million

Estimate Recalculated Jul 17, 2024 04:37PM EST

Who is Coelho Rogerio Vivaldi?

Coelho Rogerio Vivaldi has an estimated net worth of $3.76 Million. This is based on reported shares across multiple companies, which include Crinetics Pharmaceuticals, Inc., Spark Therapeutics, Inc., Sigilon Therapeutics, Inc., Minerva Neurosciences, Inc., and Bioverativ Inc..

SEC CIK

Coelho Rogerio Vivaldi's CIK is 0001610381

Past Insider Trading and Trends

2016 was Coelho Rogerio Vivaldi's most active year for acquiring shares with 8 total transactions. Coelho Rogerio Vivaldi's most active month to acquire stocks was the month of January. 2016 was Coelho Rogerio Vivaldi's most active year for disposing of shares, totalling 11 transactions. Coelho Rogerio Vivaldi's most active month to dispose stocks was the month of September. 2022 saw Coelho Rogerio Vivaldi paying a total of $1,552,400.00 for 698,750 shares, this is the most they've acquired in one year. In 2015 Coelho Rogerio Vivaldi cashed out on 142,333 shares for a total of $3,158,400.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Crinetics Pharmaceuticals, Inc. (CRNX) Snapshot price: $37.8

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+30.91%
3.4K
—
—
14.4K
Jun 7
Form 4
+120.00%
6K
—
—
11K
Jun 16
Form 4
∞
5K
$22.06
$110,300.00
5K
Jun 8
Form 4
—
0
—
—
0
Jun 17
Form 4/A
—
0
—
—
0
Jan 3
Form 4
—
0
—
—
0
Jan 3
Form 3
—
0
—
—
0
No matching records found

Spark Therapeutics, Inc. No price found

Chief Commercial Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
—
0
$29.69
-$326,824.00
18.72K
Scheduled
Jul 15
Form 4
—
0
$23.18
-$235,740.00
18.72K
Scheduled
Apr 20 - Apr 21
Form 4
—
0
—
—
0
Jan 5
Form 4
+247.69%
13.33K
$27.83
-$875,602.50
18.72K
Oct 13
Form 4
-15.67%
-1.00K
$27.67
-$1,743,300.00
5.38K
Oct 7
Form 4
+64.38%
2.5K
$23.00
$57,500.00
6.38K
Feb 4
Form 3
—
0
—
—
0
No matching records found

Sigilon Therapeutics, Inc. No price found

PRESIDENT AND CEO

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-12.17K
—
—
0
Aug 11
Form 4
+85.91%
5.53K
$19.24
$106,358.72
11.96K
Jul 21
Form 4
—
0
—
—
0
Feb 28
Form 4
—
0
—
—
0
Feb 18
Form 4
—
0
—
—
0
Jan 3
Form 4
+213.12%
50K
—
—
73.46K
Nov 4
Form 4
—
0
—
—
0
Feb 11
Form 4
∞
22.22K
—
—
22.22K
Dec 8
Form 3
—
0
—
—
0
No matching records found

Minerva Neurosciences, Inc. (NERV) Snapshot price: $11.22

President and CEO

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 3/A
—
0
—
—
0
Form 4
∞
41.67K
$6.00
$250,002.00
41.67K
Jun 30 - Jul 1
Form 3
—
0
—
—
0
No matching records found

Bioverativ Inc. No price found

EVP, Chief Global Therapeutics

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-5.76K
—
—
0
Mar 8
Form 4
+1,583.06%
4.99K
$103.52
-$220,083.52
5.3K
Feb 14
Form 4
—
0
—
—
0
Jan 31
Form 4/A
—
0
—
—
0
Feb 14
Form 4
—
0
—
—
0
Feb 14
Form 3
—
0
—
—
0
No matching records found